UNSPSC 51203003: Lobenzarit sodium

This classification denotes a nonsteroidal antiinflammatory drug with the molecular structure C14H8CLNO4.2NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 7Z9SP74BXF chemically known as benzoic acid, 2-((2-carboxyphenyl)amino)-4-chloro-, disodium salt, but more commonly known as lobenzarit sodium, which bears US NIH Compound Identifier 47462. European Medicines Agency schedules Lobenzarit sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02963MIG.

Most nations, for tariff and trade purposes, schedule lobenzarit sodium under HS 29224995 and SITC 51465. As of Q4 2014, LOBENZARIT SODIUM remains US FDA's Preferred Term for this commodity. Lobenzarit sodium bears US NLM identifiers UMLS ID C0126105 and NCI Concept Code C72817. SMILES: C1CCC(C(C1)C(=O)[O-])NC2CC(CCC2C(=O)[O-])CL.[NA+].[NA+].

UNSPSC 51203003 Lobenzarit sodium is a Commodity code that nominally covers a specific anti-inflammatory pharmaceutical ingredient, but recent state and local solicitation activity under this code does not reflect direct procurement of lobenzarit sodium. Instead, the code tags much broader pharmaceutical and medical supply purchasing — generic multi-source pharmaceuticals, over-the-counter products, naloxone and drug deactivation systems, and emergency medical consumables. State and local governments use this code to solicit medical supplies and pharmaceutical products across health departments, public health agencies, fire rescue operations, and cooperative purchasing consortia. The work includes both direct pharmaceutical manufacturer contracting and supply-chain arrangements with authorized wholesalers, bundled with compliance requirements for drug supply chain security, cGMP certification, and FDA compliance.

Recent activity shows issuing bodies spanning state health and human services commissions, county health departments, city fire departments, and multi-state cooperative purchasing alliances. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and Texas Health and Human Services Commission represent state-level repeat buyers; Seminole County, Florida and the City of Tampa represent county and municipal purchasers. Geographic spread includes Minnesota, Texas, Florida, and Oregon. Representative recent opportunities include the City of Tampa's March 2026 IFB for 169 line items of medical and first aid supplies (respirators, cardiac monitoring electrodes, endotracheal tubes, oxygen delivery systems, and consumables) for the Fire Department Rescue Division, estimated at $700,000, with a certified Small Local Business Enterprise set-aside offering a 5 percent bid discount; Seminole County's June 2026 IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually due July 26, 2023; and MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, requiring vendors to maintain relationships with authorized wholesalers and achieve 75 percent weight on price competitiveness with a two-year contract term and optional extensions through June 2028.